On June 4, 2024, BridgeBio issued a press release “announc[ing] sustained positive results from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia, ...

Mizuho Securities analyst Salim Syed assigned a Buy rating on BridgeBio Pharma (BBIO – Research Report) on June 4 and set a price target ...

In a report released on June 4, Jack Allen from Robert W. Baird maintained a Hold rating on BioMarin Pharmaceutical (BMRN – Research ...

BridgeBio Pharma, Inc. (NASDAQ: BBIO) has announced positive and sustained results from its Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia. The trial, known ...

Overview A type of bone growth disorder. Due to genetic mutations, the cartilage does not convert into a bone during fetal ...

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of ...

Today's biotech news update includes a dramatic vote on MDMA therapy, record drug shortages, bad(?) news for Biomarin, and a ...

(Exclusive) She also notes that babies with dwarfism or achondroplasia can have "larger than normal" heads. From a birthing perspective, Liz admits that carrying Leighton was "just more bearable ...

BridgeBio Pharma revealed results from the PROPEL 2 Phase 2 trial of infigratinib in children with achondroplasia. Key data ...

BBIO Price Action: At the time of writing, BridgeBio shares are trading 4.5% lower at $27.65, according to data from Benzinga Pro.

Longer follow-up results from a mid-stage trial indicate the company’s treatment for a genetic cause of dwarfism may be competitive to an approved therapy from BioMarin Pharmaceutical.